{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:11:30Z","timestamp":1790964690606,"version":"4.1.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\u03b2-Thalassemia major patients are frequently vulnerable to endocrine dysfunction due to iron overload from chronic transfusions. This impairs growth, thyroid function, glucose metabolism, and bone health, ultimately compromising quality of life and long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study investigates the prevalence and pattern of endocrine dysfunction in \u03b2-thalassemia major patients receiving iron-chelation therapy and explores associations with iron overload markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This case-control study involved 60 \u03b2-thalassemia major patients and 20 age- and sex-matched controls. Hormonal and biochemical parameters were measured and linked to iron status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among \u03b2-thalassemia major patients (7\u201335\u2009years), 73.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944\/60) were splenectomized; 36 received deferiprone, 19 deferasirox, and 5 deferoxamine. Concerning iron status, both splenectomized and non-splenectomized patients had significantly higher iron and ferritin and lower haptoglobin levels compared to controls. No significant differences were found in hepcidin or hemopexin levels. Regarding thyroid function, about 15% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20099\/60) of \u03b2-thalassemia major patients had subclinical primary hypothyroidism. Ferritin negatively correlated with free thyroxine (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u2009\u22120.330,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.010). As for glycemic status, 51.7% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200931\/60) of \u03b2-thalassemia patients had glycated hemoglobin (HbA1c) \u2a7e6.5% and 38.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200923\/60) showed impaired fasting blood sugar. With respect to metabolic markers, splenectomized patients had higher fibroblast growth factor 21 (FGF21) than the control (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.042), while no significant group differences were found in galectin-1 or sortilin. Ferritin correlated significantly and positively with FGF21 levels (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.353,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.006). With respect to calcium\u2013parathyroid\u2013vitamin D axis, hypoparathyroidism and hyperparathyroidism were each found in 11.7% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20097\/60) of \u03b2-thalassemia patients. Vitamin D levels were significantly lower in the \u03b2-thalassemia groups compared to controls (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0001) with 71.7% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200943\/60) deficient despite 43.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200926\/60) receiving supplements. Non-splenectomized patients had higher Procollagen Type I C-Peptide, a bone formation marker, compared to controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Endocrine disturbances are common in \u03b2-thalassemia major despite chelation therapy. Incorporating endocrine assessment into routine practice is essential for early detection and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420188251406554","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T04:26:31Z","timestamp":1766031991000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Endocrine complications in patients with \u03b2-thalassemia major receiving iron-chelation therapy"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-9077","authenticated-orcid":false,"given":"Ola M.","family":"Al-Sanabra","sequence":"first","affiliation":[{"name":"Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Balqa Applied University, Al-Salt, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-1879","authenticated-orcid":false,"given":"Manal A.","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan"},{"name":"Pharmacological and Diagnostic Research Centre, Al-Ahliyya Amman University, Amman 19328, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer A.","family":"Haz\u00e0a","sequence":"additional","affiliation":[{"name":"Arkan Laboratory, Zarqa, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waf\u00e0 J.","family":"Haz\u00e0","sequence":"additional","affiliation":[{"name":"Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.5937\/jomb0-37682"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97353-0"},{"key":"e_1_3_4_4_2","first-page":"272","article-title":"Alpha- and beta-thalassemia: rapid evidence review","volume":"105","author":"Baird DC","year":"2022","unstructured":"Baird DC, Batten SH, Sparks SK. Alpha- and beta-thalassemia: rapid evidence review. Am Fam Physician 2022; 105: 272\u2013280.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081921"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2022.2067605"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2020.1734124"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272419"},{"key":"e_1_3_4_9_2","first-page":"260","article-title":"Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia","volume":"63","author":"Kurtoglu AU","year":"2012","unstructured":"Kurtoglu AU, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. Endokrynol Pol 2012; 63: 260\u2013263.","journal-title":"Endokrynol Pol"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2016.1136209"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2633-y"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279046"},{"issue":"5","key":"e_1_3_4_13_2","article-title":"Serum or plasma ferritin concentration as an index of iron deficiency and overload","volume":"5","author":"Garcia-Casal MN","year":"2021","unstructured":"Garcia-Casal MN, Pasricha SR, Martinez RX, et al. Serum or plasma ferritin concentration as an index of iron deficiency and overload. Cochrane Database Syst Rev 2021; 5(5): CD011817.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/1110-1121.147614"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232124"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1629"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409808102"},{"key":"e_1_3_4_18_2","first-page":"181","article-title":"Impact of haptoglobin gene polymorphism on phenotypic variability in \u03b2-thalassemia patients: relation to iron overload and oxidative stress","volume":"13","author":"Balbaa OA","year":"2023","unstructured":"Balbaa OA, Kamel MA, Salem KS, et al. Impact of haptoglobin gene polymorphism on phenotypic variability in \u03b2-thalassemia patients: relation to iron overload and oxidative stress. Afro-Egypt J Infect Endem Dis 2023; 13: 181\u2013189.","journal-title":"Afro-Egypt J Infect Endem Dis"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V32.5.811.811"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2015.00187"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-024-04670-w"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.71000\/1wm8nt06"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-021-01116-2"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1412-7"},{"key":"e_1_3_4_25_2","article-title":"Does splenectomy influence the development of hypothyroidism in transfusion dependent thalassemia patients? A retrospective study","volume":"11","author":"Skafida M","year":"2019","unstructured":"Skafida M, Sofocleous C, Kattamis A, et al. Does splenectomy influence the development of hypothyroidism in transfusion dependent thalassemia patients? A retrospective study. Mediterr J Hematol Infect Dis 2019; 11: e2019064.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.4103\/trp.trp_4_20"},{"key":"e_1_3_4_27_2","first-page":"174","article-title":"Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study","volume":"6","author":"De Sanctis V","year":"2008","unstructured":"De Sanctis V, De Sanctis E, Ricchieri P, et al. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. Pediatr Endocrinol Rev 2008; 6: 174\u2013180.","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_3_4_28_2","article-title":"Clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent \u03b2-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM)","volume":"92","author":"De Sanctis V","year":"2022","unstructured":"De Sanctis V, Soliman A, Tzoulis P, et al. Clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent \u03b2-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM). Acta Biomed 2022; 92: e2021488.","journal-title":"Acta Biomed"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13260"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03146-y"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12224"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6573497"},{"key":"e_1_3_4_33_2","first-page":"285","article-title":"Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center","volume":"2","author":"Gamberini MR","year":"2005","unstructured":"Gamberini MR, Fortini M, De Sanctis V, et al. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2005; 2: 285\u2013291.","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_3_4_34_2","article-title":"Evolution of combined impaired fasting glucose and impaired glucose tolerance in \u03b2-thalassemia major: results in 58 patients with a mean 7.7-year follow-up","volume":"93","author":"De Sanctis V","year":"2022","unstructured":"De Sanctis V, Daar S, Soliman AT, et al. Evolution of combined impaired fasting glucose and impaired glucose tolerance in \u03b2-thalassemia major: results in 58 patients with a mean 7.7-year follow-up. Acta Biomed 2022; 93: e2022242.","journal-title":"Acta Biomed"},{"key":"e_1_3_4_35_2","article-title":"Screening for glucose dysregulation in \u03b2-thalassemia major (\u03b2-TM): an update of current evidences and personal experience","volume":"93","author":"De Sanctis V","year":"2022","unstructured":"De Sanctis V, Daar S, Soliman AT, et al. Screening for glucose dysregulation in \u03b2-thalassemia major (\u03b2-TM): an update of current evidences and personal experience. Acta Biomed 2022; 93: e2022158.","journal-title":"Acta Biomed"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7105"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.29328\/journal.hcem.1001003"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.15562\/bmj.v12i3.4772"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz309"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00038.2007"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/63.3.354"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050312119876151"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2016.08.012"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251406554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188251406554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251406554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:37:08Z","timestamp":1777592228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188251406554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"alternative-id":["10.1177\/20420188251406554"],"URL":"https:\/\/doi.org\/10.1177\/20420188251406554","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"20420188251406554"}}